VASCULAR DISRUPTING AGENTS - CURRENT MARKET LANDSCAPE
During our research, we identified 126 vascular disrupting agents that are being developed by close to 32 industry players and organizations for the treatment of different disease indications. As can be observed in the figure, majority (40%) of the companies engaged in this domain are small firms (less than 50 employees). This is followed by large (17%), and very large (27%) companies. Examples of very large players include ( in alphabetical order, no specific selection criteria ) AbbVie, Celgene, Mayo Clinic, Novartis, Sanofi Genzyme, Takeda, Teva Pharmaceutical Industries and The University of Texas MD Anderson Cancer Center. Although the efforts for developing vascular disrupting agents have been undertaken by various players across the globe, majority (54%) of them are based in North America. For additional details, please visit - https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html As can be observed in the followi...